Table 3. DFS and OS by clinicopathological parameters and expressions of all-PRLR and LF-PRLR.

Characteristics	Cases, n	DFS				OS
		Events, n	5-year survival, %	P value		Events, n	5-year survival, %	P value
Age at diagnosis, years				0.925				0.612
≤50	109	20	81.5			9	92.8
>50	226	43	82.5			23	90.4
Tumor size, mm				0.002				0.004
≤20	121	12	90.4			4	96.6
>20	214	51	77.5			28	88.1
Histological grading				0.456				0.291
I/II	196	35	84.2			16	93.5
III	139	28	79.2			16	87.9
Lymphovascular invasion				0.001				0.013
Absence	229	32	86.8			16	93.4
Presence	106	31	72.0			16	86.4
Axillary nodal metastasis				<0.001				0.001
Absence	157	14	92.0			6	95.8
Presence	178	49	735			26	87.1
Staging				<0.001				<0.001
I/II	243	28	88.8			11	95.5
III	92	35	64.6			21	79.8
ER				0.820				0.014
Negative	102	19	81.2			16	83.8
Positive	233	44	82.5			16	94.5
PR				0.302				0.005
Negative	124	26	80.5			19	84.1
Positive	211	37	83.2			13	95.4
HER2				0.317				0.028
Negative	239	43	83.8			18	93.8
Positive	96	20	78.0			14	84.7
All-PRLR				0.179				0.480
Negative/low expression	101	14	86.1			8	92.9
High expression	234	49	80.4			24	90.4
LF-PRLR				0.717				0.954
Negative expression	152	28	83.0			15	92.0
Low/high expression	183	35	81.5			17	90.4

DFS, disease-free survival; OS, overall survival; all-PRLR, all prolactin receptor isoforms; LF-PRLR, long-form prolactin receptor; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2.